PERSON – Page 18

Gilead CEO Daniel O’Day Welcomes Former Colleague Dietmar Berger as New Chief Medical Officer

5 months ago talkbio0Tagged Chief Medical Officer, Daniel, Dietmar Berger, Gilead Sciences, Neoplasms, O'Day, sanofi

Daniel O’Day, Gilead Sciences, Dietmar Berger, Sanofi, Chief Medical Officer, Oncology

Corcept’s ALS Drug Trial Misses Primary Endpoint, Yet Shows Promising Survival Benefit

5 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Benefit, Corcept, Cortisol modulator, dazucorilant, Fast Track, Identifier, Phase 2 trial, Survival

Corcept Therapeutics, Dazucorilant, ALS (Amyotrophic Lateral Sclerosis), Phase 2 trial, Survival benefit, Fast Track Designation, Cortisol modulator

Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment

5 months ago talkbio0Tagged Affordable medication, CALR gene, Eli, Eli Lilly, Obesity, Pharmaceutical Services, Self-pay, single-dose, Telemedicine, Zepbound

Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy

BenevolentAI Embarks on Strategic Overhaul to Realign with Founding TechBio Mission

5 months ago talkbio0Tagged Artificial Intelligence, BenevolentAI, biopharmaceutical development, Drug Discovery, Kenneth, Mulvany, Strategic Overhaul, TechBio mission

BenevolentAI, strategic overhaul, TechBio mission, artificial intelligence, biopharmaceutical development, drug discovery, Kenneth Mulvany

Olema Oncology Unveils Promising Data for Oral SERD Palazestrant Ahead of Phase III Trials

5 months ago talkbio0Tagged Antonio Breast Cancer Symposium, ER-positive, HER2-negative, Malignant neoplasm of breast, NAA50 gene, Olema Oncology, Oral SERD, palazestrant, Phase 3 Clinical Trials, SABCS

Olema Oncology, palazestrant, oral SERD, Phase III trials, breast cancer, ER-positive, HER2-negative, San Antonio Breast Cancer Symposium (SABCS)

Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies

5 months ago talkbio0Tagged acalabrutinib, AstraZeneca, BeiGene, Bruton's Tyrosine Kinase Inhibitors [MoA], Chronic Lymphocytic Leukemia, CLL, Continuous therapy, Effectiveness, Eli, Eli Lilly, Fixed-Duration Therapy, ibrutinib, Nemtabrutinib, Pirtobrutinib, Safety, zanubrutinib

BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety

Agios’ Thalassemia Drug Mitapivat Faces Liver Injury Concerns Despite Second Phase III Success

5 months ago talkbio0Tagged Agios, ENERGIZE-T, Injury of liver, Mitapivat, Phase 3 Clinical Trials, regulatory approval, Thalassemia

Agios Pharmaceuticals, Mitapivat, Thalassemia, Liver Injury, Phase III Trials, ENERGIZE-T Study, Regulatory Approval

BioAge Labs Discontinues Phase II Obesity Study Due to Safety Concerns, Stock Plummets

5 months ago talkbio0Tagged Azelaprag, BioAge Labs, concerns, crash, liver transaminitis, Obesity, Phase 2 Clinical Trials, Safety

BioAge Labs, azelaprag, obesity treatment, Phase II study, safety concerns, liver transaminitis, stock crash

GSK Extends Shingrix Collaboration with Zhifei in China, Explores RSV Vaccine Partnership

5 months ago talkbio0Tagged Arexvy, China, Collaboration, Respiratory syncytial virus, Shingrix, SmithKline Beecham, Vaccines, Zhifei

GSK, Zhifei, Shingrix, RSV vaccine, Arexvy, China, vaccine collaboration

ASH 2024: Anito-cel Demonstrates Enhanced Response Rate and Consistent Safety in Phase II Update for Relapsed/Refractory Multiple Myeloma

5 months ago talkbio0Tagged 2024, anito-cel, Arcellx, Asymmetric Septal Hypertrophy, Phase II Update, Profiling (action), Rating (action), relapsed/refractory multiple myeloma, Response process, Safety

ASH 2024, Anito-cel, Arcellx, Relapsed/Refractory Multiple Myeloma, Phase II Update, Response Rate, Safety Profile